The Program in Radiation Biology is focused on ways in which the effectiveness of radiotherapy can increase local tumor control and survival of cancer patients. Three different approaches are being pursued to achieve this goal: 1) Develop pharmacologic and biologic agents to combine with radiotherapy and chemotherapy to improve local tumor control and prevent metastatic spread; 2) Design new approaches to administer radiotherapy or combined modality therapy to test in clinical trials;3) Identify genetic determinants using yeast and mammalian genetics that influence the response of tumors to radiation or the combination of chemotherapy and radiation. The research of program members has resulted in a series of important findings that include the identification of Prl-3 (phosphatase of regenerating liver-3) as a p53 target gene, the identification of the molecular pathways that give rise to intercellular polarity, developing new hypoxic-specific cytotoxins for cancer therapy, identifying new genes that are essential for adaptation to stress that are essential for metastasis, elucidating the signaling pathways that integrate DNA damage recognition, checkpoint signaling and DNA repair, generation of mouse models to study in vivo stress responses and targeted therapy, expanding the use of hypofractionated radiosurgery to treat solid tumors, developing new approaches to generate protons for therapeutic use and developing molecular and functional imaging techniques to direct the delivery of radiotherapy. The 26 program members representing the School of Medicine and the School of Humanities and Sciences are supported by peer-reviewed research and training grants totaling $6,826,435, including 16 R01s, 2P01s, 2 T32s. The members of this program are highly motivated and interactive in their goal to take fundamental discoveries in the laboratory and develop them to increase the efficacy of radiotherapy to control tumor growth and metastasis.

Public Health Relevance

The overall objective of the program is to translate new findings from the laboratory to the clinic to improve radiotherapy treatment effectiveness in cancer patients and to reduce late-treatment-related toxicities.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Stanford University
United States
Zip Code
Lee, Bee L; Fan, Shenghua K; Lu, Ying (2017) A curve-free Bayesian decision-theoretic design for two-agent Phase I trials. J Biopharm Stat 27:34-43
Mohanty, Suchismita; Chen, Zixin; Li, Kai et al. (2017) A Novel Theranostic Strategy for MMP-14-Expressing Glioblastomas Impacts Survival. Mol Cancer Ther 16:1909-1921
Alcántara-Hernández, Marcela; Leylek, Rebecca; Wagar, Lisa E et al. (2017) High-Dimensional Phenotypic Mapping of Human Dendritic Cells Reveals Interindividual Variation and Tissue Specialization. Immunity 47:1037-1050.e6
Chao, Mark P; Gentles, Andrew J; Chatterjee, Susmita et al. (2017) Human AML-iPSCs Reacquire Leukemic Properties after Differentiation and Model Clonal Variation of Disease. Cell Stem Cell 20:329-344.e7
Rogers, Zoë N; McFarland, Christopher D; Winters, Ian P et al. (2017) A quantitative and multiplexed approach to uncover the fitness landscape of tumor suppression in vivo. Nat Methods 14:737-742
Sun, Ruping; Hu, Zheng; Sottoriva, Andrea et al. (2017) Between-region genetic divergence reflects the mode and tempo of tumor evolution. Nat Genet 49:1015-1024
Jin, Yuxue; Lai, Tze Leung (2017) A new approach to regression analysis of censored competing-risks data. Lifetime Data Anal 23:605-625
Clarke, Christina A; Glaser, Sally L; Leung, Rita et al. (2017) Prevalence and characteristics of cancer patients receiving care from single vs. multiple institutions. Cancer Epidemiol 46:27-33
Han, Summer S; Ten Haaf, Kevin; Hazelton, William D et al. (2017) The impact of overdiagnosis on the selection of efficient lung cancer screening strategies. Int J Cancer 140:2436-2443
Wender, Paul A; Hardman, Clayton T; Ho, Stephen et al. (2017) Scalable synthesis of bryostatin 1 and analogs, adjuvant leads against latent HIV. Science 358:218-223

Showing the most recent 10 out of 227 publications